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Background: For the fi rst time we tested an association between the human multidrug resistance gene 1 (MDR1) polymorphisms 
(SNPs) and idiopathic pulmonary fi brosis (IPF). Several MDR1 polymorphisms are associated with pathologies in which they modify 
the drug susceptibility and pharmacokinetics.  Materials and Methods: We genotyped three MDR1 polymorphisms of 48 IPF patients 
and 100 control subjects with Italian origins. Results: No evidence of association was detected.  Conclusion: Th ere are 50 known 
MDR1 SNPs, and their role is explored in terms of the eff ectiveness of drug therapy. We consider our small-scale preliminary study 
as a starting point for further research. 
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Several drugs have not been evaluated as P-gp 
substrates, so additional unidentifi ed substances could 
be transported by the P-gp across cell membrane.
Furthermore, variations in P-gp expression and function 
are associated with the pathology susceptibility[5] and 
have important consequences in therapeutic outcome and 
disease progression.[6] By now, 50 single nucleotide and 3 
insertion/deletion polymorphisms have been mapped in 
the MDRl gene.[7] To evaluate MDR1 as possible risk factor 
for IPF, we analyzed the three most commonly studied 
MDR1 polymorphisms in our case record.
MATERIALS AND METHODS
Between 2008 and 2013, 48 consecutive Italian patients 
with IPF (31 males and 17 females) were enrolled for 
this study at the Respiratory Division, Sant’Orsola 
Hospital, University of Bologna. Diagnosis of IPF was 
made according to ATS/ERS guidelines of 2011.
A total of 100 healthy volunteers (50 males and 50 
females), were enrolled as controls. The study was 
approved by the Ethical Committee of Sant’Orsola-
Malpighi General Hospital and complied with the ethical 
principles for medical research involving human subjects 
of the Helsinki declaration. WriĴ en informed consent 
was obtained from all patients and healthy controls 
INTRODUCTION
Anti-infl ammatory, anti-fi brosis, immunosuppressive 
t r e a t m e n t s  ( a z a t h i o p r i n e ,  c o r t i c o s t e r o i d s , 
cyclophosphamide) or antioxidant strategies and 
other therapeutic agents targeting fibrogenesis 
(interferons, antagonists of cytokines, growth factors or 
their receptors and angiogenic agents) are useless for 
idiopathic pulmonary fi brosis (IPF).[1] No studies have 
considered a possible relationship between the human 
multidrug resistance 1 gene (MDR1) polymorphisms 
and the therapy outcome in IPF.
Multidrug resistance 1 gene is expressed in epithelial 
cells of a certain number of organs, including the 
lung.[2] The MDR1 phenotype is acquired after 
administration of drugs[3] and when expressed, it 
extrudes chemotherapeutic substances from cells 
causing the ineff ectiveness of the treatment.[2]
The MDR1 encodes for a plasma membrane MDR 
protein, the P-glycoprotein (P-gp)[2] that functions as an 
energy-dependent membrane effl  ux pump to maintain 
cytoplasmic concentrations steady.[3] P-gp drags out of 
the cell a number of substances with diverse chemical 
structures. It is not clear how P-gp recognizes and 
transports and hence various range of compounds, but 
it is not based on simply chemical structure.[4]
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beforehand. Peripheral blood samples were drawn from 
each individual and DNA extraction was performed using 
the GenElute Blood Genomic DNA kit (Sigma, Milan, Italy).
Three single-nucleotide polymorphisms (SNPs) mapping 
respectively on exon 12 (1236C>T; rs1128503), 21 (2677G>T/A; 
rs2032582), and 26 (3435C>T; rs1045642) of MDR1 gene 
were selected. Polymorphism selection was based on data 
available from published investigations. Among all known 
gene variation, we selected three SNPs that were previously 
found associated with other pathologies, thus having higher 
chances to directly alter gene function or to be linked with 
susceptibility variation.
Each polymorphism was amplified by polymerase chain 
reaction using flanking primers (supplementary data: 
additional fi le 1) and products incubated with a restriction 
endonuclease, BsuRI, GsaI and DpnII (CABRU, Milan, Italy), 
respectively. Fragments were separated by 10% polyacrylamide 
gel electrophoresis, subsequently stained with ethidium 
bromide (supplementary data: additional fi le 2). To assess the 
accuracy of the genotyping outputs, one-third of randomly 
selected samples were blindly tested by a second operator.
The distribution of genotypes in both probands and control 
groups was tested for deviations from the Hardy-Weinberg 
equilibrium using Pearson’s Chi-square test. Association 
analyses were performed with the Unphased software v3.1.5 
in a Windows Vista operative system.[8] This included a tests 
for both allele and genotype association, as well as odds 
ratio calculation, which was shown in relation to a single 
reference allele or genotype.
Two and three SNPs combinations were considered for 
haplotype analysis. Since the likelihood ratio statistics may 
be sensitive to rare haplotypes, a frequency threshold of 0.02 
was adopted. An overall association analysis, that tested 
whether any haplotypes are associated (global P value), as 
well as a specifi c test for each haplotype,  was carried out.
RESULTS
Genotype frequency in cases and controls were distributed 
accordingly with the Hardy-Weinberg equilibrium law.
Allele frequency was similar in case and control groups at 
all the tested loci. No evidence of the association between 
IPF and MDR1 genotypes was detected [Table 1].
Multilocus approach could be more sensitive than single 
locus analysis. For this reason, two and three locus 
haplotypes were tested for association with IPF. Both 
the global and the single haplotype tests for association 
rejected the hypothesis of the association between MDR1 
polymorphisms and IPF (data not shown).
DISCUSSION
C1236T, G2677T/A and C3435T are the most commonly 
studied among the 50 known MDR1 gene SNPs in disease 
conditions and diff erent populations. We did not fi nd any 
differences about the frequencies of these three MDR1 
polymorphisms between IPF patients and control subjects 
in our Italian case study. The relatively low number of 
patients examined could be the cause of false negative results, 
especially if MDR1 had minor eff ects on risk to develop IPF. 
Moreover, additional untyped polymorphisms could have an 
eff ect on IPF risk. This is only the start point to evaluate the 
role of the MDR1 SNPs in IPF considering the large amount 
of SNPs to analyze and the diff erences determined by the 
 Table 1: Case-control association analysis between MDR1 SNPs and IPF
SNP ID Allele/
genotype
IPF 
case
Control IPF-
frequency
Co-
frequency
Chi-
square
P OR (CI)
rs1128503 C 58 111 0.60 0.56 0.64 0.42 Reference
T 38 89 0.40 0.44 0.82 (0.50-1.34)
CC 18 33 0.38 0.33 0.67 0.72 Reference
CT 22 45 0.46 0.45 0.90 (0.42-1.93)
TT 8 22 0.17 0.22 0.67 (0.25-1.80)
rs2032582 T 57 108 0.59 0.54 0.76 0.38 Reference
A 39 92 0.41 0.46 0.80 (0.49-1.32)
TT 17 32 0.35 0.32 1.07 0.59 Reference
TA 23 44 0.48 0.44 0.98 (0.45-2.1)
AA 8 24 0.17 0.24 0.63 (0.23-1.69)
rs1045642 C 52 100 0.54 0.50 0.45 0.50 Reference
T 44 100 0.46 0.50 0.85 (0.52-1.38)
CC 14 29 0.29 0.29 1.31 0.52 Reference
CT 24 42 0.50 0.42 1.18 (0.53-2.67)
TT 10 29 0.21 0.29 0.71 (0.27-1.87)
IPF = Idiopathic pulmonary fi brosis; OR = Odds ratio; CI = Confi dence interval; MDR1 = Multidrug resistance 1 gene; SNPs  = Single-nucleotide polymorphisms
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variety of ethnic populations.[9] In fact, signifi cant diff erences 
in the frequencies of MDR1 haplotypes have been found 
among Caucasian, African-American, and Asian-American 
population.[6] We believe that further understanding of 
the correlation between the MDR1 genetic variations and 
the physiology and biochemistry of P-gp may be critically 
important for the development of new treatment modalities 
and personalized pharmacotherapy for patients with IPF.
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Additional fi le 1: Characteristics of polymorphisms
SNP ID Primer sequences 5’-3’ Nucleotide 
changea
Location Tab Restriction 
enzyme
rs1128503 For TTGAATGAAGAGTTTCTGATGTTTT 1236C>T Exon 12 45°C BsuRI
Rev CTCTGCATCAGCTGGACTGT
rs2032582 For TGTTGTCTGGACAAGCACTGA 2677G>T Exon 21 55°C GsaI
Rev TGTGAAGACAATGGCCTGAA
rs1045642 For GGCTCCGAGCACACCTGGGCA 3435C>T Exon 26 59°C DpnII
Rev GGCCAGAGAGGCTGCCACATGCT
aMajor allele/minor; bAnnealing temperature; Conditions of amplifi cation for 35 cycles were 30 s at 94°C, 30 s at specifi c Tab, 30 s at 72°C and fi nal extension for 8 min at 72°C; 
SNP: Single-nucleotide polymorphism
aMajor all
Additional fi le 2: Electrophoretic pattern on 10% acrylamide gel of multidrug 
resistance 1 gene polymerase chain reaction-restriction fragment length 
polymorphism genotyping assays: a) 1236C>T rs1128503 (exon 12), the PCR 
product of 237 bp has two restriction sites, b) 2677 G>T/A rs2032582 (exon 21), 
c) 3435C>T rs1045642 (exon 26). Numbers on the side represent fragments’ 
length expressed in base pairs.
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